Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Co-administration of ribavirin and didanosine is not recommended. Exposure to didanosine or its
active metabolite (dideoxyadenosine 5’-triphosphate) is increased in vitro when didanosine is co-
administered with ribavirin. Reports of fatal hepatic failure as well as peripheral neuropathy,
pancreatitis, and symptomatic hyperlactataemia/lactic acidosis have been reported with use of
ribavirin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Co-administration of ribavirin and didanosine is not recommended. Exposure to didanosine or its
active metabolite (dideoxyadenosine 5’-triphosphate) is increased in vitro when didanosine is co-
administered with ribavirin. Reports of fatal hepatic failure as well as peripheral neuropathy,
pancreatitis, and symptomatic hyperlactataemia/lactic acidosis have been reported with use of
ribavirin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Sofosbuvir is a nucleotide prodrug. After oral administration of Sovaldi, sofosbuvir is rapidly
absorbed and subject to extensive first-pass hepatic and intestinal metabolism. Intracellular hydrolytic
prodrug cleavage catalysed by enzymes including carboxylesterase 1 and sequential phosphorylation
steps catalysed by nucleotide kinases result in formation of the pharmacologically active uridine
nucleoside analogue triphosphate. The predominant inactive circulating metabolite GS-331007 that
accounts for greater than 90% of drug-related material systemic exposure is formed through pathways
sequential and parallel to formation of active metabolite. The parent sofosbuvir accounts for
approximately 4% of drug-related material systemic exposure (see section 5.2). In clinical
pharmacology studies, both sofosbuvir and GS-331007 were monitored for purposes of
pharmacokinetic analyses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Sofosbuvir is a nucleotide prodrug. After oral administration of Sovaldi, sofosbuvir is rapidly
absorbed and subject to extensive first-pass hepatic and intestinal metabolism. Intracellular hydrolytic
prodrug cleavage catalysed by enzymes including carboxylesterase 1 and sequential phosphorylation
steps catalysed by nucleotide kinases result in formation of the pharmacologically active uridine
nucleoside analogue triphosphate. The predominant inactive circulating metabolite GS-331007 that
accounts for greater than 90% of drug-related material systemic exposure is formed through pathways
sequential and parallel to formation of active metabolite. The parent sofosbuvir accounts for
approximately 4% of drug-related material systemic exposure (see section 5.2). In clinical
pharmacology studies, both sofosbuvir and GS-331007 were monitored for purposes of
pharmacokinetic analyses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage ab556887163921e3de959dedb2c53a699c6d6e2aff931920c005b7b2e8863d0f · Zeichen 0–887 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.